Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalDiabetesNeuropathyTrial Update

Study Compares 3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy

The ongoing trial comparing 3D printed insoles to ready-to-wear options could significantly impact the diabetic neuropathy treatment landscape. Positive results may drive a shift towards personalized medical devices in diabetes management, influencing market dynamics and competitive positioning.

Published: June 18, 2026
Updated: June 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / Neuropathy
Asset: Neuropathy
Trial SummaryCLN

Phase III

Diabetes / Neuropathy

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The ongoing trial comparing 3D printed insoles to ready-to-wear options could significantly impact the diabetic neuropathy treatment landscape. Positive results may drive a shift towards personalized medical devices in diabetes management, influencing market dynamics and competitive positioning.

Why it matters

The ongoing trial comparing 3D printed insoles to ready-to-wear options could significantly impact the diabetic neuropathy treatment landscape. Positive results may drive a shift towards personalized medical devices in diabetes management, influencing market dynamics and competitive positioning.

What changed

Trial Update

Analysis

A randomized controlled trial is underway to evaluate the effectiveness of 3D printed insoles compared to ready-to-wear insoles in diabetic neuropathy patients.

The ongoing trial comparing 3D printed insoles to ready-to-wear options could significantly impact the diabetic neuropathy treatment landscape. Positive results may drive a shift towards personalized medical devices in diabetes management, influencing market dynamics and competitive positioning.

Monitor the trial results and participant feedback at the 4 and 8-week assessments.

Related companies & assets

Assets

  • Neuropathy →

Sources & Humanexa intelligence

Source links

  • 3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy ↗
  • Study Compares 3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy ↗

Related Humanexa pages

  • Study Compares 3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.